Tislelizumab vs Toripalimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Tislelizumab

Marketed by BeOne Medicines and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03358875 · Phase 3 · completed

The 805-participant trial was randomized and actively controlled with docetaxel, and its co-primary clinical endpoint of overall survival was met in both the full population and the PD-L1-positive subgroup. However, treatment assignment was not blinded, so despite the large sample and statistically significant survival results, the evidence is rated moderate rather than strong.

Next expected readout: November 2026 · NCT06704620 (registry estimate)

No aligned efficacy figure on record for this race.

Toripalimab

Marketed by Coherus BioSciences, Inc. and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03856411 · Phase 3 · completed

This randomized, quadruple-blind, placebo-controlled trial of 465 patients met its primary endpoint: median progression-free survival was 8.4 months with toripalimab plus chemotherapy versus 5.6 months with placebo plus chemotherapy, a highly statistically significant improvement.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2026 · NCT06426511 (registry estimate)

Reported efficacy

MPR rate in stage III population evaluated by BIPR (up to 7 weeks after neoadjuvant); EFS in stage III population evaluated by investigators (up to 3 years); MPR rate in stage II-III population evaluated by BIPR (up to 7 weeks after neoadjuvant); EFS in stage II-III population evaluated by investigators (up to 3 years): Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met. (met)

Result source: NCT04158440

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointTislelizumabToripalimab
PFS, median7.6 vs 5.5vs Paclitaxel + Carboplatinn 120NCT03594747
5 other results
8.4 vs 5.6a+2.8 vs placeboNCT03856411
OS, median26.1 vs 19.4vs Paclitaxel + Carboplatinn 120NCT03594747
1 other result
—Not posted · NCT03856411
ORR74.2% vs 47.9%vs Paclitaxel + Carboplatinn 120NCT03594747
3 other results
  • 73.9% vs 47.9% n 119 · Phase 3 · secondary NCT03594747
  • 70% vs 49.6% n 120 · Phase 3 · secondary NCT03594747
  • 78.2% vs 49.6% n 119 · Phase 3 · secondary NCT03594747
—Not posted · NCT03856411
Duration of response, median8.4 vs 4.3vs Paclitaxel + Carboplatinn 89NCT03594747
3 other results
—Not posted · NCT03856411

PFS, median

Tislelizumab
7.6 vs 5.5vs Paclitaxel + Carboplatinn 120NCT03594747
5 other results
Toripalimab
8.4 vs 5.6a+2.8 vs placeboNCT03856411

OS, median

Tislelizumab
26.1 vs 19.4vs Paclitaxel + Carboplatinn 120NCT03594747
1 other result
Toripalimab
—Not posted · NCT03856411

ORR

Tislelizumab
74.2% vs 47.9%vs Paclitaxel + Carboplatinn 120NCT03594747
3 other results
  • 73.9% vs 47.9% n 119 · Phase 3 · secondary NCT03594747
  • 70% vs 49.6% n 120 · Phase 3 · secondary NCT03594747
  • 78.2% vs 49.6% n 119 · Phase 3 · secondary NCT03594747
Toripalimab
—Not posted · NCT03856411

Duration of response, median

Tislelizumab
8.4 vs 4.3vs Paclitaxel + Carboplatinn 89NCT03594747
3 other results
Toripalimab
—Not posted · NCT03856411
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Tislelizumab: 2 of 4 rows · Toripalimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTislelizumabToripalimab
Dropout rate
n/a: no completion milestoneTislelizumab + Nab-paclitaxel + Caa
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
n/a: no completion milestoneTislelizumab + Paclitaxel + Carbop
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
—
Discontinued due to AEs
—Tislelizumab + Nab-paclitaxel + Caa
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
—Tislelizumab + Paclitaxel + Carbop
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
—
Serious AEs
46.6%Tislelizumab + Nab-paclitaxel + Caa
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
46.7%Tislelizumab + Paclitaxel + Carbop
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
—
Most frequent reported AEs
a
anaemia 94.1%
alopecia 69.5%
neutrophil count decreased 61.9%
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
anaemia 89.2%
alopecia 65%
neutrophil count decreased 65%
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
—

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tislelizumab

Overall Survival 26.1 vs 19.4 Paclitaxel + Carboplatin months
time to event · months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
23.3 vs 19.4 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
ORR 74.2% (n=120) vs 47.9% (n=121) Paclitaxel + Carboplatin
responder rate · % of participants
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
73.9% (n=119) vs 47.9% (n=121) Paclitaxel + Carboplatin
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
70% (n=120) vs 49.6% (n=121) Paclitaxel + Carboplatin
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
78.2% (n=119) vs 49.6% (n=121) Paclitaxel + Carboplatin
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
Duration of Response 8.4 vs 4.3 Paclitaxel + Carboplatin months
time to event · months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
8.6 vs 4.3 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
10.6 vs 4.8 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
8.8 vs 4.8 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-LC13 Chest Pain 0.4 score @ 15wk
absolute change · score
No placebo or comparator arm
Chest pain
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-0.4 score @ 15wk
Chest pain
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ LC13 Cough -7 score @ 15wk
absolute change · score
No placebo or comparator arm
Coughing
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-0.4 score @ 15wk
Coughing
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 GHS 2.4 score @ 15wk
absolute change · score
No placebo or comparator arm
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
3.3 score @ 15wk
NCT03594747 · Phase 3 · registry result, not featured evidence · combination

Nasopharyngeal Carcinoma

Shared mechanism: PD-1 · full Nasopharyngeal Carcinoma pipeline

Tislelizumab

Marketed by BeOne Medicines and partners

Phase 3 in Nasopharyngeal Carcinomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06177301 (registry estimate)

No aligned efficacy figure on record for this race.

Toripalimab

Marketed by Coherus BioSciences, Inc. and partners

Approved in Nasopharyngeal Carcinomamonoclonal antibody
Partial signal

NCT03581786 · Phase 3 · completed

JUPITER-02 was a randomized, double-blind, placebo-controlled Phase 3 in 289 patients with recurrent or metastatic nasopharyngeal carcinoma. Its primary endpoint, independently reviewed progression-free survival, is a clinical outcome and was met (HR 0.52). Figures are from the FDA label; the sources read give no power calculation, so the grade is moderate.

Next expected readout: December 2026 · NCT06323239 (registry estimate)

Reported efficacy

IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1 (up to 2 years): Primary endpoint, IRC-assessed PFS: median 11.7 vs 8.0 months, hazard ratio 0.52 (95% CI 0.36 to 0.74), toripalimab plus gemcitabine-cisplatin vs placebo plus gemcitabine-cisplatin (LOQTORZI label, JUPITER-02). (met)

Result source: NCT03581786

Results for Nasopharyngeal Carcinoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Tislelizumab: registry results are on file for Nasopharyngeal Carcinoma, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Toripalimab
Primary endpoint, IRC-assessed PFS: median 11.7 vs 8.0 months, hazard ratio 0.52 (95% CI 0.36 to 0.74), toripalimab plus gemcitabine-cisplatin vs placebo plus gemcitabine-cisplatin (LOQTORZI label, JUPITER-02). NCT03581786 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tislelizumab's landscape · Toripalimab's landscape